

Treating Asthma Differently




Over 200 million people suffer from asthma worldwide

Asthma is a common condition that, despite available treatments, continues to limit patients' activities, places a heavy burden on child and adult emergency care resources, and can be fatal.

The World Health Organization (WHO) reports 340 million people suffer from asthma worldwide, with 418,000 total deaths each year. The Centre for Disease Control and Prevention (CDC) reports 25 million people in the USA suffer from asthma with 1.6 million visits to the emergency department per year. The CDC reports that Asthma affects 17% of the US population. Inhalers can have reduced effectiveness in an acute asthmatic attack due to poor technique and reduced air entry due to bronchoconstriction and airway inflammation. About 25% - 40% of asthmatic patients require additional treatment versus conventional inhalers.

The global asthma treatment market is expected to reach USD\$26.0 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period (Fortune Business Insights).



AazeinTx Inc. - Treating Asthma Differently

Founded in August 2020, AazeinTx is a clinical-stage biotechnology company dedicated to improving patients' lives with asthma. AazeinTx is developing an oral small molecule therapeutic that targets a novel neural-mediated airway reflex pathway to rapidly reverse asthmatic bronchoconstriction. AazeinTx is ready to begin a phase IIa clinical trial pending successful financing of CAD\$5 million.

AazeinTx's technology (NEO6860) targets the nervous system via a novel pathway (TRPV1), quickly stopping asthmatic attacks while at the same time reducing lung inflammation, making subsequent attacks less likely. Users will take the medication by pill, thus avoiding blocked lung issues, a primary limitation of inhalers.

NEO6860 has a robust safety profile and is rapidly effective when treating acute asthma attacks in animal models. AazeinTx is gearing up for a clinical trial to test its new therapy on asthmatic attacks and plans to investigate its long-term benefits in improving lung health to help prevent attacks from occurring. AazeinTx has secured the patent of this pathway for asthma and is concluding negotiations to secure the intellectual property of NEO6860.